$SLXN News

Silexion Therapeutics Announces 1-For-10 Reverse Share Split Of Ordinary Shares, Effective May 28

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Q1 EPS $(0.85) Beats $(1.29) Estimate

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics Announces Data From Its Current Translational Immuno-Oncology Trial Of SIL204 Shows Increase In Surface Expression Of Major Histocompatibility Complex Class I

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics Initiates Good Manufacturing Practice Clinical Batch Manufacturing Of SIL204 In Support Of Planned Upcoming Phase 2/3 Clinical Trial In LAPC

Silexion Therapeutics shares are trading lower. The company announced the submission of a Clinical Trial Application to Germany for its planned Phase 2/3 clinical trial of its lead, siRNA product candidate, SIL204.

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics Announces Successful Submission Of Its German Clinical Trial Application For The Phase 2/3 Clinical Trial Of Its SIL204 Candidate In Patients With Locally Advanced Pancreatic Cancer

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Secures Regulatory Approval To Launch Phase 2/3 Trials Of SIL204 RNAi Therapy Targeting KRAS-Driven Pancreatic Cancer

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics Q4 EPS $(1.40) Misses $(1.07) Estimate

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

Silexion Targets Human Trials in 2026 After Strong Progress Against KRAS Cancers

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer